In the current post-genomic era large-scale efforts are underway to functionally explore the proteome by assembling large antibody libraries. However, since many proteins are modified posttranslationally to regulate their function, collections of modification-specific sensors are also needed.
INTRODUCTION
In the current post-genomic era large-scale efforts are underway to study the emerging proteome. Antibodies, because of their ability to bind their respective targets with extremely high specificity, are essential tools in this endeavor. In fact, non-profit organizations like the European "ProteomeBinders" consortium (1) and the "Clinical Proteomic Technologies for Cancer" network (2) as well as commercial enterprises are currently sponsoring large projects to assemble allinclusive antibody libraries.
In order to regulate their function many proteins are altered after their initial synthesis. Since such posttranslational modifications change the physicochemical properties of a given protein, this further increases the complexity of the proteome. The true challenge therefore is to have not only all-inclusive antibody libraries but also to assemble collections of sensors, which specifically detect posttranslational changes.
One of the best-studied modifications after polypeptide synthesis is reversible protein phosphorylation through the action of specific kinases and phosphatases. A plethora of cellular processes hinge upon the correct phosphorylation state of key regulators (3) and errors may result in cell death or malignancy (4) . It is therefore not surprising that protein phosphorylation represents a very active area of research in the quest for new therapeutic cancer targets (5) . Phospho-specific antibodies, first described over 25 years ago (6) (7) (8) , represent key tools in the study of cellular processes regulated by phosphorylation. Their production, however, is relatively costly and time consuming.
In our laboratory we have succeeded in obtaining highly functional conformation-specific recombinant antibodies using the method of phage display (9,10 and unpublished data). This not only allowed us to follow the fate of proteins upon activation, but also demonstrated that the diversity of available recombinant antibody libraries is sufficiently broad. We thus decided to use a similar approach for the selection of phosphospecific antibodies. As the antigen we chose GRASP65, the predominant phosphoprotein of mitotic Golgi membranes (11) . Careful studies have mapped several phospho-residues of this structural Golgi protein and phosphospecific antibodies have been generated using classical methods (12) (13) (14) .
The present study describes a novel approach, which allowed the direct selection and characterization of three distinct highly functional monoclonal phosphospecific antibodies.
EXPERIMENTAL PROCEDURES
Antigen preparation-Poly-His-tagged fulllength rat GRASP65 was expressed in E. coli and purified on Ni-NTA 5 beads as described (12) . The still bound protein was enzymatically phosphorylated by incubating it at 37°C with mitotic cell extract prepared as described before (15) . After washing six times, the protein was eluted with a 200-mM-imidazole-containing buffer followed by dialysis in PBS/20 mM β-glycerolphosphate.
Successful modification was confirmed using the mobility shift assay described before (11) . Prior to phage display the antigen was biotinylated using EZ-Link Maleimide PEO 2 -Biotin (Pierce).
Antibody selection using phage display-The Griffin.1 library-protocol was used with modifications as published before (16, 17) . After three rounds of affinity selection, 80 and 96 clones, respectively, were randomly selected and analyzed using two approaches. First, clones were analyzed directly by immunofluorescence using scFv-containing bacterial supernatants and HeLa cells transfected with rat GRASP65-GFP or nontransfected NRK cells. From all positive clones (34 in total) plasmids were extracted and the scFvcoding region sequenced. In the second approach clones were first screed for the presence of antibodies by PCR using the primers 5'-CA GGA AAC AGC TAT GAC-3' and 5'-TGA ATT TTC TGT ATG AGG-3'. Amplified products were cleaned using a 96-well-format kit (MacheryNagel) and then sequenced. Known and duplicate scFv were discarded. The remaining unique positive clones were subcloned into an Fccontaining mammalian expression vector (see above). Subsequently produced full antibodies were analyzed on immunofluorescence using NRK cells.
Characterization of selected antibodies-For the postfixation treatment with λ-phosphatase (New England Biolabs), cells were fixed in paraformaldehyde and permeabilized with TritonX100. After washing in PBS, cells were subsequently incubated for one hour at 30°C in the presence of the enzyme in TET buffer (50 mM Tris pH 7.5, 0.1 mM EDTA, 0.01% TritonX-100, 2 mM MnCl 2 ) before immunofluorescence staining.
For epitope mapping purified His-tagged GRASP65 full-length protein (wild type and various mutants mA, mB, mC, mD, mE, mF, mG, mH, mI and mJ where known/potential phosphorylation sites had been mutated to alanines) were incubated with mitotic or interphase cytosol at 37°C for one hour and then were further subjected to one round of purification with Ni-NTA beads. The eluates were resolved with SDS-PAGE and probed with the indicated antibodies on Western-blot.
For more detailed Experimental procedures see Supplementary Online Material.
RESULTS
The full-length antigen is synthesized in bacteria and directly phosphorylated. Classical methods to obtain phosphospecific antibodies require the design and subsequent synthesis of highly specific short phospho-peptides, which are ultimately used for animal immunization. In stark contrast for our in vitro approach, the full-length protein can be used. In a first step, rodent GRASP65 fused to a poly-histidine tag was produced in bacteria. It was next purified on Ni-NTA resin and then directly phosphorylated by exposing it to kinase-containing mitotic cell extract, prepared as described before (15) . Finally, the now enzymatically phosphorylated full-length antigen was eluted. Prior to antibody selection successful modification was confirmed using a mobility shift assay (11) as shown in Figure 1A .
Three distinct scFv are identified after affinitybased in vitro selection of antibodies. Using the phosphorylated full-length GRASP65 protein as antigen (immobilized on magnetic beads) singlechain variable fragment (scFv) antibodies were selected starting with a semi-synthetic phagemid library and using a protocol essentially as described before (17). Briefly, several rounds of affinity selection and amplification were performed. After the third round, randomly picked clones were analyzed by testing bacterially produced scFv through immunofluorescence on GRASP65-overexpressing mammalian cells. Additionally, unique scFv were identified using upfront DNA sequencing directly from bacterial colonies followed by immunofluorescence.
Combining the two approaches, three distinct antibodies, R3F2, RB7 and R3G3, were retained for further analysis. R3F2 was the most abundant scFv antibody, representing approximately 15% of all clones, while the two others were each retrieved only once. Prior to further characterization they were subcloned into a human-Fc-domain containing vector as described before (18) , thus generating dimeric antibodies (hR3F2, hRB7 and hR3G3) with enhanced avidity and greater ease of use. In this format, all three antibodies clearly labeled perinuclear Golgi-like structures also of non-transfected cells (Fig. 1B) . Furthermore, they easily detected bacterially produced rat GRASP65 on immunoblot. This was, however the case only if the antigen had first been exposed to mammalian cell extract (Fig. 1B) .
We noticed that hR3F2 and hRB7, when used for immunofluorescence only labeled a subset of cells. Detailed analysis revealed Golgi membrane staining exclusively in dividing cells
( Supplementary Figures 1 and 2 ). Since phosphorylation of GRASP65 mostly takes place at the onset of mitosis (11, 13) this strongly suggested recognition of an epitope modified by a mitotic kinase. In contrast, hR3G3 labeled intracellular structures of all cells, though staining of mitotic cells was more pronounced. This implied binding of this third scFv to either a nonmodified residue or to an epitope modified by both interphase and mitotic kinases.
All three selected scFv specifically and exclusively bind rodent GRASP65. In coimmunofluorescence experiments, the antibody labeling of all three scFv strongly overlapped with that of other Golgi markers including GRASP65, detected by a monoclonal antibody named 7E10 (19) . All three selected antibodies readily recognized overexpressed GRASP65 while none bound to overexpressed GRASP55, which is closely related to GRASP65. Protein expression knockdown with GRASP65-specific siRNA led to a loss of immunofluorescence signal (data not shown). All three antibodies, while readily staining cells of rodent origin, never decorated human cells. Species specificity was confirmed through immunofluorescence analysis of a mixed HeLa cell population, where cells stably expressing rat GRASP65 were mixed with wildtype HeLa cells. All three antibodies bound the recombinant rodent protein while non-transfected cells were never stained (Supplementary Figure 3) .
All three selected antibodies are phosphospecific.
Our immunofluorescence and immunoblot data (Fig. 1B) suggested that all three antibodies would specifically recognize phosphoepitopes. To confirm this, FR3T3 cells were fixed, permeabilized and incubated with a broad-acting lambda phosphatase to dephosphorylate cellular proteins. Subsequent immunofluorescence analysis showed loss of labeling by all three selected antibodies while staining with nonphosphospecific antibodies was not affected (Fig. 1C and Supplementary Figure 4) . Furthermore, a GRASP65 mutant, in which eight known/putative phospho-residues had been replaced by alanines, was -unlike the wild-type protein -no longer recognized by any of the three antibodies (data not shown). This not only confirmed the lambda-phosphatase experiment but also suggested that the antibody epitopes would be found among those eight residues.
The specific target for each of the three antibodies is determined. In a last set of experiments, epitope mapping for all three phosphospecific antibodies was performed through immunoblotting and the use of a set of GRASP65 mutants with substitutions of known/putative phosphoamino acids (Fig. 2A) . For hR3F2, phospho-serine at position 376 was found as the epitope since the antibody failed to recognize any construct in which this residue had been mutated (mC, mE, mF, mG, mI in Fig. 2B-E) . The second mitosis-specific antibody, hRB7, displayed an identical pattern ( Fig. 2D and E) , thus representing a distinct second phosphorylation sensor against the same epitope. Previously it has been shown that pS376 is modified by the mitotic kinase Cdk1-Cyclin B and polyclonal phosphospecific antibodies have generated a staining pattern very similar to that seen with our selected hR3F2 and hRB7 (13) .
Finally, epitope mapping was also performed for the third antibody, hR3G3. Analysis of binding patterns of this scFv to the different mutant constructs enabled identification of pS277 as the antibody's target (see mB in Fig. 2B and C) . This finding is again in agreement with published data; it has been shown that this serine residue at position 277 is phosphorylated in both interphase and during mitosis by the action of two distinct kinases (14) .
DISCUSSION
Our presented work describes a novel antibody selection approach where the antigen is prepared by enzymatically phosphorylating the full-length target protein and where then antibodies are subsequently obtained utilizing a fully in vitro affinity-based selection process. Using the example of GRASP65, a well-studied Golgi phospho-protein, we show that highly functional conformation specific sensors can be obtained: in one screen three distinct scFv against two different phospho-epitopes were found and subsequently characterized.
Our method has several inherent advantages over animal-based techniques (schematically depicted in Fig. 3) . First, the in vitro approach requires less time and resources. It allows skipping the steps of selection, synthesis and injection of short synthetic phospho-peptides as antigen usually needed for the production of phosphospecific antibodies and uses the fulllength protein directly during the antibody selection process. Classical methods depend on a robust immune response by the mammalian host and entail a fair amount of animal experimentation, including the need for repeated immunizations often with multiple different antigens. Thus, routinely milligram-quantities of several different phospho-peptides and a significant time investment are required since either purification of the obtained serum to remove nonspecific binders or, in case of classic monoclonal antibodies, screening of a large number of hybridoma clones are necessary. In our animal-free method microgram amounts of the bacterially produced antigen are sufficient and high-quality scFv antibodies can be obtained in a few days fully in vitro. Successful antibody selection is independent of the target protein's recognition by the immune system and the selected antibodies can be analyzed at the molecular level since their encoding nucleotide sequences are readily available.
An even more distinct advantage of our method, however, lies in the fact that there is no necessity to determine the phospho-residue composition of the protein of interest prior to antibody production. Since the entire selection process occurs in vitro, events activated after the injection of animals, such as protein degradation, dephosphorylation and antigen processing, are all circumvented. The entire, full-length protein prepared and enzymatically modified under quasi-physiologic conditions can thus be used directly as the antigen. This way, in a single phage display screen, multiple phosphospecific antibodies targeted at more than one phospho-epitope can be selected as evidenced by the present study. Furthermore, our approach may favor the selection of antibodies against the major phosphorylation site(s) of a given antigen. Indeed, two of the selected scFv were found to bind one and the same residue, and one of them (R3F2) was by far the most abundant antibody found in the screen. Their target residue, pS376, represents one of the key phospho-residues on GRASP65 (13).
Intriguingly, no non-phosphospecific antibodies were obtained using our method. While this is a seeming paradox, previous work in our laboratory has similarly led to the selection of scFv, which exclusively bind active domains. For instance, only antibodies specifically recognizing the GTPbound form were obtained when using as antigens the small GTPases Rab6 (10) and Rab1 (unpublished data). Upon activation through GTPloading (or analogously through phosphorylation) new protein-protein interaction domains are formed on the molecule's surface. In contrast to animal-based approaches, the in vitro selection process relies on the recognition of three dimensional, rather that linear, epitopes, and is thus biased toward these interaction domains since they represent ideal binding sites for antibodies. Altogether this is yet another argument in favor of our approach since it may more efficiently yield highly functional conformation sensors and help determine the major phosphorylation site of a given protein.
Finally, our approach benefits from inherent advantages of the recombinant approach. Selected antibody clones can be stored as plasmids and at a fraction of the cost, all but eliminating the risk of losing a clone. Antibodies can be produced in an endless supply and with high reproducibility, including as fully humanized antibodies synthesized by mammalian cells. Since the Fcportion to which a given scFv would be fused can be chosen freely, various versions of the antibody, with the same variable regions but differing Fc fragments (mouse, rabbit, human, etc.) can be produced as has been described by our laboratory recently (18) . Finally, additional modifications including fusions to fluorescent tags can be made easily.
In summary, we have described a novel in vitro approach, which allows selecting high-quality phosphospecific antibodies directly from fulllength phosphorylated antigens and with obviating the need for upfront phospho-residue mapping. In order to meet the challenges of understanding the proteome in all its complexity, collections of such modification-specific sensors will have to be assembled in addition to already existing antibody libraries. We strongly believe that our in vitro approach, by providing a simple and robust alternative to classical methods, while at the same time offering savings in both time and resources, will be a reliable tool in this endeavor. 2. Epitope mapping reveals pS376 (for hR3F2 and hRB7) and pS277 (for R3G3) as phospho-targets. A, Schematic depiction of known and putative phosphorylation sites and used Histagged mutants. B -E, Phospho-epitope mapping. Purified full-length His-tagged GRASP65 constructs (either wild type or phosphorylation-deficient mutants) were incubated with interphase (B) or mitotic (C -E) cell extracts, loaded in equal amounts onto separate gels, resolved with SDS-PAGE and transferred onto nitrocellulose. Loss of signal for a given construct indicates that at least one of the mutated phosphoresidues must be present as wild type and be phosphorylated for antibody binding. FIGURE 3. Schematic comparison of the classic with the in vitro approaches to obtain phosphospecific antibodies. For both approaches the antigen is produced in full length and then phosphorylated (top portion shaded in gray). In the classic in vivo method (left, shaded in blue), phosphoepitope mapping through mass spectrometry, selection of the phospho-epitope to be targeted and synthesis of a short phospho-peptide to be injected are all performed before immunization of animals. Additionally, downstream affinity purification, or alternatively, screening of a large number of hybridoma clones must be performed. Overall this process takes months and yields one serum or one monoclonal antibody directed against one predefined epitope. In the here presented in vitro approach (right, shaded in red) upfront phosphoamino acid identification is omitted and the full-length antigen is used directly for antibody selection. Random clones are analyzed and eventually Fc-portion-containing antibodies are produced. In total, this approach takes only weeks, allows direct access to the antibody's DNA and has the potential of leading to several distinct monoclonal antibodies in endless supply directed against multiple epitopes.
by guest on October 5, 2017 
